医学
内科学
化学免疫疗法
替莫唑胺
伊立替康
进行性疾病
神经母细胞瘤
肿瘤科
粒细胞集落刺激因子
无进展生存期
胃肠病学
外科
化疗
癌症
环磷酰胺
结直肠癌
生物
遗传学
细胞培养
作者
Benjamin Joshua Lerman,Yimei Li,Cecilia A. Carlowicz,Meaghan P. Granger,Thomas Cash,Arhanti Sadanand,Katherine M. Somers,Aeesha Ranavaya,Brian Weiss,Michelle Choe,Jennifer Haunani Foster,Navin R. Pinto,Daniel A. Morgenstern,Margarida Rafael,Keri A. Streby,Rachel N. Zeno,Rajen J. Mody,Sahr Yazdani,Ami Vijay Desai,Margaret E. Macy
摘要
PURPOSE: Although chemoimmunotherapy is widely used for treatment of children with relapsed high-risk neuroblastoma (HRNB), little is known about timing, duration, and evolution of response after irinotecan/temozolomide/dinutuximab/granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSF) therapy. PATIENTS AND METHODS: Patients eligible for this retrospective study were age < 30 years at diagnosis of HRNB and received ≥ 1 cycle of I/T/DIN/GM-CSF for relapsed or progressive disease. Patients with primary refractory disease who progressed through induction were excluded. Responses were evaluated using the International Neuroblastoma Response Criteria. RESULTS: -amplified in 50 of 134 (37%). Seventy-one patients (49%) had an objective response to I/T/DIN/GM-CSF (objective response; 29% complete response, 14% partial response [PR], 5% minor response [MR], 21% stable disease [SD], and 30% progressive disease). Of patients with SD or better at first post-I/T/DIN/GM-CSF disease evaluation, 22% had an improved response per International Neuroblastoma Response Criteria on subsequent evaluation (13% of patients with initial SD, 33% with MR, and 41% with PR). Patients received a median of 4.5 (range, 1-31) cycles. The median progression-free survival (PFS) was 13.1 months, and the 1-year PFS and 2-year PFS were 50% and 28%, respectively. The median duration of response was 15.9 months; the median PFS off all anticancer therapy was 10.4 months after discontinuation of I/T/DIN/GM-CSF. CONCLUSION: Approximately half of patients receiving I/T/DIN/GM-CSF for relapsed HRNB had objective responses. Patients with initial SD were unlikely to have an objective response, but > 1 of 3 patients with MR/PR on first evaluation ultimately had complete response. I/T/DIN/GM-CSF was associated with extended PFS in responders both during and after discontinuation of treatment. This study establishes a new comparator for response and survival in patients with relapsed HRNB.
科研通智能强力驱动
Strongly Powered by AbleSci AI